CT-P10 (Truxima™): A Rituximab Biosimilar

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Emma D Deeks

Abstract

CT-P10 (Truxima™) is the first biosimilar of the reference monoclonal anti-CD20 antibody rituximab. It is approved for use in all indications for which reference rituximab is approved, including follicular lymphoma (FL), diffuse large B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis (RA), granulomatosis with polyangiitis and microscopic polyangiitis. CT-P10 has similar physicochemical and pharmacodynamic properties to those of reference rituximab, and the pharmacokinetic biosimilarity of the agents has been shown in patients with RA or FL. CT-P10 demonstrated clinical efficacy equivalent to that of reference rituximab in patients with RA, and was generally well tolerated in this population as well as in patients with FL. The tolerability, immunogenicity and safety profiles of CT-P10 were similar to those of reference rituximab, and switching from reference rituximab to CT-P10 had no impact on safety or efficacy. The role of reference rituximab in the management of autoimmune conditions and cancers is well established and CT-P10 provides an effective biosimilar alternative for patients requiring rituximab therapy.

Citations

Sep 10, 2019·Expert Opinion on Biological Therapy·Ju-Yang JungChang-Hee Suh
Sep 13, 2017·Journal of Oncology Practice·Håkan Mellstedt
Oct 31, 2017·Neurology. Neuroimmunology and Neuroinflammation·Divyanshu DubeyOlaf Stüve
Aug 3, 2017·Expert Review of Clinical Pharmacology·Bertrand Coiffier
Feb 13, 2019·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Su Jung KimWon Yong Han
Sep 29, 2020·Recent Patents on Anti-cancer Drug Discovery·Romeo G Mihăilă

❮ Previous
Next ❯

Methods Mentioned

BETA
glycosylation

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Skin Therapy Letter
K GleghornM Wilkerson
Vojnosanitetski pregled. Military-medical and pharmaceutical review
Biljana MihaljevićMilan Petrovic
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
T A DavisR Levy
BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Kate McKeage
© 2022 Meta ULC. All rights reserved